BENEFICIAL EFFECT OF BROMOCRIPTINE ON HIGH FAT DIET-INDUCED BODY WEIGHT GAIN, ADIPOSITY AND BIOCHEMICAL ANOMALIES IN WISTAR RATS
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i6.17843Keywords:
Obesity, Bromocriptine, High-fat diet, DopamineAbstract
 Objectives: Dopamine plays a critical role in various vital functions, including hormonal regulation, reward, emotions, and food intake. It affects on the multiple aspects of food intake that include food selection, satiety, and energy expenditure. Dopamine D2 receptors (D2R) were found to be lower in several brain regions in both obese experimental animals and humans, and it has been observed that dopamine D2 agonist bromocriptine (BC) can exert favorable metabolic changes in seasonal obesity. The aim of this study was to investigate the beneficial effect of chronic administration of BC a central dopamine receptor agonist on body weight gain, adiposity, and biochemical anomalies in rats.
Methods: In this study, chronic administration of BC (2.5 and 5 mg/kg/day, i.p) a dopamine agonist for 8 weeks along with high-fat diet (HFD) to the obese rats which were pretreated with HFD feeding for 8 weeks on the various parameters of obesity were analyzed. The effects of these treatments on body weight, feed intake (kcal), weight and size of fat pads, levels of serum glucose, triglycerides (TG), total cholesterol (TC), high-density lipoproteins (HDL), and low-density lipoprotein were analyzed.
Results: Treatment with BC (2.5 and 5 mg/kg/day, i.p) produced significant dose-dependent decrease (p<0.05) in body weight gain, feed intake (kcal), weight and size of fat pads, levels of serum glucose, TG, TC, and low-density lipoproteins as compared to HFD group. Moreover, the level of serum HDL was increased as compared to HFD group. BC a dopamine receptor agonist positively modulate the parameters of obesity, and the effect was comparable to orlistat, a well-reported drug for obesity.
Conclusion: In conclusion, the study demonstrates that BC ameliorated established obesity and associated biochemical consequences.
Downloads
References
Verma RK, Paraidathathu T. Herbal medicines used in the traditional Indian medicinal system as a therapeutic treatment option for overweight and obesity management: A review. Int J Pharm Pharm Sci 2014;6:40-7.
McIntyre AM. Burden of illness review of obesity: Are the true costs realised? J R Soc Health 1998;118(2):76-84.
Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007;8 Suppl 1:13-7.
Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209.
Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
Carpenter KM, Hasin DS, Allison DB, Faith MS. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: Results from a general population study. Am J PublicHealth 2000;90(2):251-7.
Foster GD, Wadden TA. Psychology of obesity, weight loss, and weight regain: Clinical and research findings. In: Blackburn GL, Kanders BS, editors. Obesity: Pathophysiology, Psychology and Treatment. New York: Chapman and Hall; 1994. p. 140-66.
Kushner RF, Foster GD. Obesity and quality of life. Nutrition 2000;16(10):947-52.
Khaserao S, Somani R. Evaluation of anti-obesity activity of solasodine in high fat diet-induced obesity in rat. Int J Pharm Pharm Sci 2017;9:23-9.
Bloom SR, Kuhajda FP, Laher I, Pi-Sunyer X, Ronnett GV, Tan TM, et al. The obesity epidemic: Pharmacological challenges. Mol Interv 2008;8(2):82-98.
Khorassani FE, Misher A, Garris S. Past and present of antiobesity agents: Focus on monoamine modulators. Am J Health Syst Pharm 2015;72(9):697-706.
Xu Y, Tong Q. Expanding neurotransmitters in the hypothalamic neurocircuitry for energy balance regulation. Protein Cell 2011;2(10):800-13.
Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000;404(6778):672-7.
Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404(6778):661-71.
Wang GJ, Nora DV, Jean L, Naomi RP, Christopher TW, Wei Z, et al. Brain dopamine and obesity. Lancet 2001;357:354-7.
Berthoud HR. Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 2002;26(4):393-428.
Kelley AE. Ventral striatal control of appetitive motivation: Role in ingestive behavior and reward-related learning. Neurosci Biobehav Rev 2004;27(8):765-76.
Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: Expression of a thrifty†genotype underlying the metabolic syndrome? Eur J Pharmacol 2003;480(1-3):125-31.
Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999;100(1):3-16.
Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005;52(4):313-20.
Malik Z, Sharma PL. An ethanolic extract from licorice (Glycyrrhiza glabra) exhibit anti-obesity effects by decreasing dietary fat absorption in a high fat diet-induced obesity rat model. IJPSR 2011;2:3010-8.
Lin TB, Lo MJ, Huang CY, Ting H, Lee SD. GABAergic modulation of ventilatory response to acute and sustained hypoxia in obese Zucker rats. Int J Obes (Lond) 2005;29(2):188-95.
Brannan T, MartÃnez-Tica J, Di Rocco A, Yahr MD. Low and high dose bromocriptine have different effects on striatal dopamine release: An in vivo study. J Neural Transm Park Dis Dement Sect 1993;6(2):81-7.
Bernardis LL, Luboshitsky R, Bellinger LL, McEwen G. Nutritional studies in the weanling rat with normophagic hypothalamic obesity. J Nutr 1982;112(7):1441-55.
Arçari DP, Bartchewsky W, dos Santos TW, Oliveira KA, Funck A, Pedrazzoli J, et al. Antiobesity effects of yerba maté extract (Ilex paraguariensis) in high-fat diet-induced obese mice. Obesity (Silver Spring) 2009;17(12):2127-33.
Prats E, Monfar M, Castellà J, Iglesias R, Alemany M. Energy intake of rats fed a cafeteria diet. Physiol Behav 1989;45(2):263-72.
Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 2011;57(5):611-24.
Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 1986;251:E576-83.
Woods SC, Seeley RJ, Rushing PA, D’Alessio D, Tso P. A controlled high-fat diet induces an obese syndrome in rats. J Nutr 2003;133(4):1081-7.
Ikemoto S, Thompson KS, Takahashi M, Itakura H, Lane MD, Ezaki O. High fat diet-induced hyperglycemia: Prevention by low level expression of a glucose transporter (GLUT4) minigene in transgenic mice. Proc Natl Acad Sci U S A 1995;92(8):3096-9.
Valladolid-Acebes I, Merino B, Principato A, Fole A, Barbas C, Lorenzo MP, et al. High-fat diets induce changes in hippocampal glutamate metabolism and neurotransmission. Am J Physiol Endocrinol Metab 2012;302(4):E396-402.
Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000;71(1):68-78.
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, et al. Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147(1):77-84.
Berridge KC, Robinson TE. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28(3):309-69.
Davis LM, Michaelides M, Cheskin LJ, Moran TH, Aja S, Watkins PA, et al. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology 2009;89(2):152-62.
Clifton PG, Rusk IN, Cooper SJ. Stimulation and inhibition of food intake by the selective dopamine D2 agonist, N-0437: A meal pattern analysis. Pharmacol Biochem Behav 1989;33(1):21-6.
Hattori S, Naoi M, Nishino H. Striatal dopamine turnover during treadmill running in the rat: Relation to the speed of running. Brain Res Bull 1994;35(1):41-9.
MacRae PG, Spirduso WW, Walters TJ, Farrar RP, Wilcox RE. Endurance training effects on striatal D2 dopamine receptor binding and striatal dopamine metabolites in presenescent older rats. Psychopharmacology (Berl) 1987;92(2):236-40.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
